SCHULMAN AMY W — SEC insider filings

SEC reporting owner CIK 1438226. 31 insider filings on record with FilingPulse; latest filed 2026-11-12.

Transaction summary — filings shown

Covers all 31 filings on record, filed 2020-10-30 to 2026-11-12. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Camp4 Therapeutics Corp (CAMP)10% owner34 legs · 3,125,369 sh · $21,999,979—16
ALNYLAM PHARMACEUTICALS, INC. (ALNY)Director141 leg · 1,910 sh · $299,5264 legs · 30,200 sh · $5,264,54620
SQZ Biotechnologies Co (SQZ)Director, 10% owner74 legs · 253,700 sh · $4,040,367—25
FRACTYL HEALTH, INC. (GUTS)Director31 leg · 8,550 sh · $9,964—2
Elevance Health, Inc. (ELV)Director3—1 leg · 26 sh · $7,4752
Hudson Executive Investment Corp. II (HCII)Director1——1

Insider filings — SCHULMAN AMY W

FiledFormIssuerReported transactionsSource
2026-11-124ALNYLAM PHARMACEUTICALS, INC. (ALNY)Purchase (P): 1,910 @ $156.82EDGAR
2026-05-224ALNYLAM PHARMACEUTICALS, INC. (ALNY)Grant/award (A): 838 @ $0 · Grant/award (A): 1,802 (derivative) @ $0EDGAR
2026-05-154Elevance Health, Inc. (ELV)Grant/award (A): 563 @ $0EDGAR
2026-05-144ALNYLAM PHARMACEUTICALS, INC. (ALNY)Option exercise (M): 11,250 @ $70.20 · Option exercise (M): 11,250 (derivative) @ $0EDGAR
2026-03-234Elevance Health, Inc. (ELV)Sale (S): 26 @ $287.50EDGAR
2026-02-034Elevance Health, Inc. (ELV)Grant/award (A): 218 @ $0EDGAR
2025-09-114Camp4 Therapeutics Corp (CAMP)
jointly with Polaris Management Co. VII, L.L.C., Polaris Partners VII, L.P., Polaris Entrepreneurs' Fund VII, L.P., Polaris Partners X, L.P., Polaris Partners GP X, L.L.C., Chee Brian
Purchase (P): 1,221,721 @ $1.53 · Purchase (P): 85,468 @ $1.53EDGAR
2025-06-134FRACTYL HEALTH, INC. (GUTS)Grant/award (A): 22,500 (derivative) @ $0EDGAR
2025-05-124ALNYLAM PHARMACEUTICALS, INC. (ALNY)Grant/award (A): 775 @ $0 · Grant/award (A): 1,558 (derivative) @ $0EDGAR
2025-03-174FRACTYL HEALTH, INC. (GUTS)Purchase (P): 8,550 @ $1.17EDGAR
2025-03-144ALNYLAM PHARMACEUTICALS, INC. (ALNY)Option exercise (M): 2,750 @ $131.21 · Option exercise (M): 2,750 (derivative) @ $0EDGAR
2024-10-224/ACamp4 Therapeutics Corp (CAMP)
jointly with Polaris Management Co. VII, L.L.C., Polaris Partners VII, L.P., Polaris Entrepreneurs' Fund VII, L.P., Polaris Partners X, L.P., Polaris Partners GP X, L.L.C., Chee Brian
Conversion (C): 1,250,061 · Conversion (C): 87,448 · Conversion (C): 353,718 · Conversion (C): 24,745 · Purchase (P): 909,090 @ $11 · Conversion (C): 14,020,475 (derivative) · +3 moreEDGAR
2024-10-154Camp4 Therapeutics Corp (CAMP)
jointly with Polaris Management Co. VII, L.L.C., Polaris Partners VII, L.P., Polaris Entrepreneurs' Fund VII, L.P., Polaris Partners X, L.P., Polaris Partners GP X, L.L.C.
Conversion (C): 1,250,061 · Conversion (C): 87,448 · Conversion (C): 353,718 · Conversion (C): 24,745 · Purchase (P): 909,090 @ $11 · Conversion (C): 14,020,475 (derivative) · +3 moreEDGAR
2024-06-274ALNYLAM PHARMACEUTICALS, INC. (ALNY)Option exercise (M): 8,500 @ $131.21 · Sale (S): 8,500 @ $240 · Option exercise (M): 8,500 (derivative) @ $0EDGAR
2024-05-314ALNYLAM PHARMACEUTICALS, INC. (ALNY)Option exercise (M): 30,000 @ $66.83 · Sale (S): 10,121 @ $148.21 · Sale (S): 11,516 @ $148.93 · Sale (S): 63 @ $149.76 · Option exercise (M): 30,000 (derivative) @ $0EDGAR
2024-05-204ALNYLAM PHARMACEUTICALS, INC. (ALNY)Grant/award (A): 5,228 (derivative) @ $0EDGAR
2024-02-054Fractyl Health, Inc. (GUTS)Grant/award (A): 45,000 (derivative) @ $0EDGAR
2023-06-154SQZ Biotechnologies Co (SQZ)Grant/award (A): 39,875 (derivative) @ $0EDGAR
2023-05-194ALNYLAM PHARMACEUTICALS, INC. (ALNY)Grant/award (A): 3,454 (derivative) @ $0EDGAR
2023-02-274ALNYLAM PHARMACEUTICALS, INC. (ALNY)Option exercise (M): 136 @ $0 · Option exercise (M): 136 (derivative) @ $0EDGAR
2022-06-164SQZ Biotechnologies Co (SQZ)Grant/award (A): 20,000 (derivative) @ $0EDGAR
2022-05-204ALNYLAM PHARMACEUTICALS, INC. (ALNY)Grant/award (A): 5,153 (derivative) @ $0EDGAR
2022-02-254ALNYLAM PHARMACEUTICALS, INC. (ALNY)Grant/award (A): 136 (derivative) @ $0EDGAR
2021-12-234SQZ Biotechnologies Co (SQZ)Option exercise (M): 10,091 @ $2.02 · Option exercise (M): 7,458 @ $4.59 · Option exercise (M): 6,581 @ $4.59 · Option exercise (M): 10,091 (derivative) @ $0 · Option exercise (M): 7,458 (derivative) @ $0 · Option exercise (M): 6,581 (derivative) @ $0EDGAR
2021-12-154SQZ Biotechnologies Co (SQZ)Purchase (P): 1,850 @ $10.88 · Purchase (P): 1,850 @ $10.94EDGAR
2021-10-294ALNYLAM PHARMACEUTICALS, INC. (ALNY)Grant/award (A): 1,814 (derivative) @ $0EDGAR
2021-07-194ALNYLAM PHARMACEUTICALS, INC. (ALNY)Grant/award (A): 4,032 (derivative) @ $0EDGAR
2021-06-174SQZ Biotechnologies Co (SQZ)Grant/award (A): 10,500 (derivative) @ $0EDGAR
2021-04-144Hudson Executive Investment Corp. II (HCII)Purchase (P): 20,000 (derivative) @ $0.00EDGAR
2020-11-034SQZ Biotechnologies Co (SQZ)Conversion (C): 22,204 · Conversion (C): 161,994 · Conversion (C): 2,315,652 · Conversion (C): 275,860 · Purchase (P): 16,346 @ $16 · Purchase (P): 233,654 @ $16 · +11 moreEDGAR
2020-10-304SQZ Biotechnologies Co (SQZ)Grant/award (A): 7,055 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2020-10-29 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1438226 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs